| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911011 | Lung Cancer | 2014 | 4 Pages |
Abstract
Temozolomide 200Â mg/m2/day for 5 days in 28-day cycles is tolerable and active in patients with relapsed SCLCs. No treatment-limiting prolonged cytopenias were observed, making this our preferred schedule for further studies. Acquisition of archived biospecimens is feasible and necessary in order to continue evaluating the role of MGMT as a predictive biomarker in SCLCs.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Marjorie G. Zauderer, Alex Drilon, Kyuichi Kadota, Kety Huberman, Camelia S. Sima, Isabella Bergagnini, Dyana K. Sumner, William D. Travis, Adriana Heguy, Michelle S. Ginsberg, Andrei I. Holodny, Gregory J. Riely, Mark G. Kris, Lee M. Krug,